Image Analysis Group and Ferring Announce Partnership

Image Analysis Group and Ferring Announce Partnership

Image Analysis Group and Ferring Announce Partnership

Image Analysis Group and Ferring Pharmaceuticals aim to advance Women’s Reproductive Health through AI-driven medical image analysis.

London, UK – 31 October 2023  – IAG, Image Analysis Group, an innovative medical imaging company, announce collaboration with Ferring Pharmaceuticals, to use Artificial Intelligence (AI)-driven medical image analysis to advance women’s reproductive health, by unveiling hidden patterns and relationships within data that elude human observation.

“The collaboration with IAG exemplifies our dedication to AI-driven research and development in the intricate realm of pregnancy”, says Dr. Philippe Pinton, Senior Vice President, Head of Clinical and Translational Sciences, Global R&D at Ferring Pharmaceuticals.

 Dr. Olga Kubassova, CEO of IAG, commented:

“It is our pleasure to support the Ferring team. Together, our objective is to harness AI to reveal deeper insights into women’s reproductive health and bring the joy of delivering a healthy baby to women around the world.”

At IAG, we are committed to helping pharmaceutical partners to efficiently develop novel life-changing medicines, by leveraging our expertise in medical imaging and AI. The partners will utilize the power of IAG’s proprietary platform DYNAMIKA, developed to maximize efficiencies of handling large volumes of imaging data in multi-centre trials or across multiple trials and its integrated AI modules. This partnership holds the potential to bring innovative approaches to support women worldwide.

About IAG, Image Analysis Group 

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models. For more information, visit www.ia-grp.com.

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Dr Kubassova joins Fast Growth Icons & Female Founders Reception

Dr Kubassova joins Fast Growth Icons & Female Founders Reception

Dr Kubassova joins Fast Growth Icons & Female Founders Reception

Dr Olga Kubassova, CEO of IAG, Image Analysis Group joins the invitation-only network for founders & CEOs of the most successful fast growing scaleups, the Fast Growth Icons, London, 25th May 2023 and the Female Founders reception on the 24th May at Eight Club Moorgate.

Dr Kubassova is the CEO and Founder of IAG, investment professional in Biocapital Impact Fund and Analytics Ventures and scientist. She founded IAG, Image Analysis Group in 2007, straight after her PhD in Computer Science, and grew it into a global multi-million revenue organization, with headquarters in London, UK and offices in Philadelphia, USA and Hyderabad, India. Today, IAG has just under 100 full time staff, delivered over 400 global trials and pioneered use of Artificial Intelligence powered methods in drug development.

IAG’ team built many last partnerships and scientific collaborations with pharmaceutical, biotech and medtech companies and closely works with over 500 global clinical academic institutions.

‘It started with an idea that the world of drug development can benefit from novel technological advances, AI and digital infrastructure. Today, IAG helps to accelerate drug development and lower investment risks by using our proprietary platform DYNAMIKA, modern trial infrastructure and AI. We run imaging part of clinical trials, ensure the speed and cost-effectiveness, while delivering true insights about novel mechanisms of action and patients’ response, in real-time.’

IAG’s management team has ambitious growth plans and planning to create a high-impact, sustainable and fearlessly innovative company.

Fast Growth Icon’s mission is ‘creating the 100m+ revenue stars of the future. Fast Growth Icons provides the three pivotal things you need to deliver a breakout success Motivation – Inspirational founders share their success and failure stories and prepare you for the realities of being a founder of a business valued over $1b; Knowledge – Open dialogue amongst peers about the issues that matter, our guests consistently feedback being blown away by the quality of discussion and energy in the room; Connections – everyone is the founder of CEO of an impressive scaleup because a strong network and knowing who to get help from is key to fast-tracking growth.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. www.ia-grp.com

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Dr Kubassova joins Rothschild’s Healthcare Dinner the National Gallery

Dr Kubassova joins Rothschild's Healthcare Dinner the National Gallery

Dr Kubassova joins Rothschild’s Healthcare Dinner the National Gallery

Dr Olga Kubassova, CEO of IAG, Image Analysis Group joins Rothschild’s Healthcare Dinner the National Gallery, London, UK, 26th May 2023.

Dr Kubassova, is the CEO and Founder of IAG, investment professional and scientist. She is a mathematician with 10+ years expertise in actively managing innovation in life science companies, asset positioning, strategy and capital raising. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.

 

About Rothchild and Co

Rothschild & Co is a multinational investment bank and financial services company, and the flagship of the Rothschild banking group controlled by the French and British branches of the Rothschild family. They are a leading global financial services group, with seven generations of family control and a history of over 200 years at the centre of the world’s financial markets.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. www.ia-grp.com

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

IAG and AltruBio Partner to Deploy IAG’s AI methods in GI

IAG and AltruBio Partner to Deploy IAG's AI methods in GI

IAG and AltruBio Partner to Deploy IAG’s AI methods in GI

SAN FRANCISCO, May 08, 2023 – AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company specializing in the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced a joint poster presentation with their partner Image Analysis Group (IAG) at the Digestive Disease Week® conference, held at McCormick Place in Chicago, IL, from May 6-9, 2023.

David T. Rubin, M.D., Professor of Medicine and Pathology at the University of Chicago and AltruBio Scientific Advisory Board member, will present proof of concept data utilizing a novel AI-powered method developed by IAG for the analysis of patient tissue from AltruBio’s Phase 2b open label study of immune checkpoint enhancer (ICE) ALTB-168, in patients with moderately to severely active anti-TNFα and/or anti-integrin refractory ulcerative colitis (UC).

“Using AI tools for histology simplifies the interpretation of histological samples and offers promise in establishing a new gold standard of histological assessment in clinical trials, as well as providing earlier signals for interpretation beneficial to both patients and scientists,” said Dr. Rubin.

Jesse Hall, M.D., Chief Medical Officer of AltruBio, added,

“IAG’s AI-powered technology accurately supports histological assessment of treatment response to our ICE in development. We plan to continue clinical validation of targeting PSGL-1 to treat autoimmune and inflammatory diseases and share further progress this year.”

Key data highlights include an 87% correlation between AI Tool-determined Nancy Indices and those conducted by an expert pathologist. The AI Tool also demonstrated a 93% decrease in automatically detected neutrophils for subjects who achieved clinical remission.

Poster Presentation Details:

Session Title: AGA IBD: Disease Activity Assessment Session Date & Time: May 8, 2023 from 12:30 PM to 1:30 PM CDT (UTC –5) Presentation Title: A Novel AI Tool is Accurate at Interpreting Histology and Detects Response to ALTB-168 Therapy in Patients with Moderate to Severe Ulcerative Colitis: Proof of Concept

About AltruBio Inc.

AltruBio is a privately held biotechnology company headquartered in San Francisco that focuses on developing novel therapeutics for the treatment of immunological diseases with high unmet medical needs. Its first-generation molecule, ALTB-168, has achieved proof of mechanism in four autoimmune and inflammatory diseases. The next-generation ICE, ALTB-268, is currently being evaluated in a Phase 1 clinical trial.

About Digestive Disease Week Digestive Disease Week®

DDW is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology. More information can be found at www.ddw.org.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Dr Kubassova joins OMERACT meeting, Colorado Springs, May 2023

Dr Kubassova joins OMERACT meeting, Colorado Springs, May 2023

Dr Kubassova joins OMERACT meeting, Colorado Springs, May 2023

Dr Olga Kubassova, CEO of IAG, Image Analysis Group joins OMERACT meeting in Colorado Springs, Denver, 1-5 May 2023.

OMERACT is a global, volunteer-driven not for profit organization committed to improving outcomes for patients with autoimmune and musculoskeletal diseases through advancing the design and quality of clinical studies.

Dr Kubassova will be involved into sessions dedicated to the development of Core Outcome Sets (COS), identifying patient and disease-relevant to be measured and the corresponding measurements instruments for use in clinical trials and for regulatory approval.

This meeting is a critical event to the community and attended by the world-class domain experts, clinicians and the industry representatives to collaboratively define the state of the art outcome measures that can advance immunology research.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. www.ia-grp.com

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events